Received Mar 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
developed blood clots; suffered a stroke; This is a spontaneous report received from a Consumer or other non HCP. A female patient received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: THROMBOSIS (hospitalization, medically significant), outcome "unknown", described as "developed blood clots"; CEREBROVASCULAR ACCIDENT (hospitalization, medically significant), outcome "unknown", described as "suffered a stroke". Clinical course: reporter was writing to inquire about potential legal action or compensation programs related to the Pfizer COVID-19 vaccine. Reporter's daughter (patient) received the vaccine as a requirement for her employment. Subsequently, she developed blood clots and suffered a stroke. She is currently residing in a nursing facility requiring 24/7 care, and reporter have assumed responsibility for her child. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.